LUMAKRAS vs OPDIVO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 18, 2026·How we rate

Possible drug interaction. LUMAKRAS and OPDIVO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	LUMAKRAS	OPDIVO
Rating	72/100	72/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	SOTORASIB	NIVOLUMAB
Manufacturer	Amgen Inc	Bristol Myers Squibb
Dosage forms	Tablet	Injectable
Drug class	—	Programmed Death Receptor-1 Blocking Antibody
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma	Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma

lumakras opdivo

Rating

72/100

Pharmacy pays

—

Type

Active ingredient

SOTORASIB

NIVOLUMAB

Manufacturer

Amgen Inc

Bristol Myers Squibb

Dosage forms

Tablet

Injectable

Drug class

—

Programmed Death Receptor-1 Blocking Antibody

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma

Urinary Bladder Neoplasms, Non-Small-Cell Lung Carcinoma, Squamous Cell Carcinoma

Frequently asked questions

Which is better-rated, Lumakras or Opdivo?

Lumakras and Opdivo are tied at 3.6 out of 5 by our independent rating.

What is the difference between Lumakras and Opdivo?

Lumakras contains Sotorasib, while Opdivo contains Nivolumab — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.